Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1716362

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Cancer: Artificial Intelligence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 May 2024 to Question 24269 on Lung Cancer: Artificial Intelligence, which (a) NHS trusts have and (b) imaging network has not received funding.
tabling member constituency	Hove
tabling member printed	Peter Kyle
uin	25291
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>Since the initial announcements regarding funding for National Health Service trusts to integrate artificial intelligence into lung cancer imaging, adjustments have been made to the list of participants. Three trusts have withdrawn from the initiative, and five additional trusts have been onboarded, due to the inclusion of a new imaging network. As a result, as set out in the answer of 7 May 2024, there are now 66 trusts across 12 imaging networks that are participating in this initiative.</p><p>In the answer of 7 May 2024, 63 out of 66 trusts, in 11 of 12 imaging networks, had received funding. It is now confirmed that all 66 trusts in the 12 imaging networks participating have received or are in the process of receiving funding. These trusts are currently implementing artificial intelligence technologies to enhance diagnostic capabilities in lung cancer, consistent with the Government's commitment to advancing healthcare technology across the NHS.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:24:50 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4505 label Biography information for Peter Kyle

1716421

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions she (a) has had and (b) plans to have with (i) charities and (ii) other organisations working to secure UK access to new drugs for (A) incurable, (B) relapsing and (C) remitting cancers such as myeloma.
tabling member constituency	Birmingham, Yardley
tabling member printed	Jess Phillips
uin	25238
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>Department ministers and officials regularly meet with a range of organisations, with an interest in securing patient access to new cancer medicines. The National Institute for Health and Care Excellence (NICE) is the body that develops authoritative, evidence-based guidance for the National Health Service on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits, including medicines for myeloma. The NICE aims to publish guidance on all new medicines close to the point of licensing wherever possible, and has recommended many cancer medicines for NHS use that are now available to NHS patients, including through the Cancer Drugs Fund.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:43:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4370 label Biography information for Jess Phillips

1716422

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she (a) has had discussions and (b) plans to have discussions with the National Institute for Health and Care Excellence on (i) its use of the new severity modifier and (ii) how it (A) measures and (B) reports the impact of the modifier on approval of treatments for (1) cancers, (2) relapsing and remitting conditions and (3) conditions that are more prevalent in older people.
tabling member constituency	Birmingham, Yardley
tabling member printed	Jess Phillips
uin	25239
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>The Department regularly meets with colleagues in the National Institute for Health and Care Excellence (NICE) to discuss a range of issues, including in relation to the NICE’s methods for the evaluation of medicines. In 2022, the NICE introduced a number of changes to make its methods and processes fairer, faster, and more consistent. This includes the introduction of a broader severity modifier, in place of the end-of-life modifier. Since the changes were introduced, 79% of the NICE’s appraisals of cancer medicines carried out under the updated methods have recommended the use of the treatment for some or all of the eligible patient population, either for routine use or use through the Cancer Drugs Fund. The approval rate for all cancer appraisals carried out since 2009, when the end-of-life modifier was introduced, is 78%.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:48:27 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4370 label Biography information for Jess Phillips

1716566

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liver Diseases: Shropshire
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure there are effective pathways for early detection of liver disease in Shropshire.
tabling member constituency	North Shropshire
tabling member printed	Helen Morgan
uin	25400
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>Early detection of liver disease is vital to enable interventions, and encourage behavioural changes that can potentially lead to recovery. Liver disease is one of the primary risk factors for liver cancer. Across the Shropshire, Telford, and Wrekin Integrated Care Board (ICB) area, the early detection of liver disease is led by primary care partners, and the ICB encourages general practitioners to follow best practice in the delivery of patient care pathways, to ensure the early detection of liver disease in patients. The Shrewsbury and Telford Hospital NHS Trust is working with primary care partners to increase awareness and provide tools to support this work. The hospital also carries out active outreach into the community for drug and alcohol patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:39:47 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4934 label Biography information for Helen Morgan

1715989

registered interest
date	07/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Injuries: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an estimate of when single-step scaffold insertion will be available on the NHS for people with torn cartilage injuries.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	24913
answer	answer is ministerial correction date of answer 10/05/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently consulting on draft interventional procedures guidance that recommends single-step scaffold insertion as an option for repairing symptomatic chondral knee defects, with standard arrangements in place for clinical governance, consent, and audit. The NICE currently expects to publish final guidance in September 2024. Once the NICE has published final guidance, National Health Service organisations will be expected to take it fully into account, but the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 10/05/2024 13:49:44 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4131 label Biography information for Jim Shannon

1715999

registered interest
date	07/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Leukaemia: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to improve research into acute myeloid leukaemia.
tabling member constituency	Lancaster and Fleetwood
tabling member printed	Cat Smith
uin	24951
answer	answer is ministerial correction date of answer 09/05/2024 answer text <p>The Department is proud to invest £1.3 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was over £121.8 million for 2022/23, and more is spent on cancer than any other disease group.</p><p> </p><p>The Government, through the NIHR, is committed to improving research into the cancers with the poorest survival rates, such as acute myeloid leukaemia, by funding high quality, timely research that leads to improved outcomes for patients and the public, and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with pancreatic cancer, and other less survivable cancers. The following table shows NIHR research spend on diagnosis, treatment, and diagnosis and treatment of blood cancers, which includes leukaemia, since 2018:<br></p><table><tbody><tr><td><p>Number of projects</p></td><td><p>Total awards value</p></td></tr><tr><td><p>Blood cancer diagnosis</p></td><td><p>11</p></td><td><p>£11,900,000</p></td></tr><tr><td><p>Blood cancer treatment</p></td><td><p>14</p></td><td><p>£14,700,000</p></td></tr><tr><td><p>Blood cancer diagnosis and treatment</p></td><td><p>4</p></td><td><p>£7,700,000</p></td></tr></tbody></table><p><br> In 2023, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers, via the Medical Research Council’s two-day cancer sandpit strategic funding opportunity, focused on technological innovation for understanding cancers with the poorest survival rates.</p><p><br> The NIHR continues to encourage and welcome applications for research into any aspect of human health, including acute myeloid leukaemia. All applications are assessed for funding by peer review committees. The level of research spend in a particular area is driven by factors including the quality of the proposals, and their scientific potential. All applications for research into pancreatic cancer and other less survivable cancers, made through open competition, have been funded.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 09/05/2024 13:32:26 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4436 label Biography information for Cat Smith

1716182

registered interest
date	07/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare Products Regulatory Agency: Recruitment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will provide an update on the status of the recruitment process for the Chair of the MHRA.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	24882
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>The Government is in the process of recruiting a Chair to the Medicines and Healthcare products Regulatory Agency. The application and assessment process has concluded, and an announcement will be made when all required checks and approvals have been completed.</p><p>The process will run in accordance with the Civil Service Senior Appointments Protocol. A Civil Service Commissioner will chair this recruitment process in line with appointments of this level of seniority, and will consider the role of any incoming Chair in that process.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 24883 24884 24885 question first answered 13/05/2024 08:21:05 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1604 label Biography information for Mr Virendra Sharma

1716183

registered interest
date	07/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare Products Regulatory Agency: Recruitment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when she plans to announce the new Chair of the MHRA.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	24883
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>The Government is in the process of recruiting a Chair to the Medicines and Healthcare products Regulatory Agency. The application and assessment process has concluded, and an announcement will be made when all required checks and approvals have been completed.</p><p>The process will run in accordance with the Civil Service Senior Appointments Protocol. A Civil Service Commissioner will chair this recruitment process in line with appointments of this level of seniority, and will consider the role of any incoming Chair in that process.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 24882 24884 24885 question first answered 13/05/2024 08:21:05 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1604 label Biography information for Mr Virendra Sharma

1716184

registered interest
date	07/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare Products Regulatory Agency: Recruitment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what role the incoming Chair of the MHRA will have in the recruitment process for the new Chief Executive.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	24884
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>The Government is in the process of recruiting a Chair to the Medicines and Healthcare products Regulatory Agency. The application and assessment process has concluded, and an announcement will be made when all required checks and approvals have been completed.</p><p>The process will run in accordance with the Civil Service Senior Appointments Protocol. A Civil Service Commissioner will chair this recruitment process in line with appointments of this level of seniority, and will consider the role of any incoming Chair in that process.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 24882 24883 24885 question first answered 13/05/2024 08:21:05 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1604 label Biography information for Mr Virendra Sharma

1716185

registered interest
date	07/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare Products Regulatory Agency: Recruitment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will provide an update on the status of the recruitment process for the Chief Executive of the MHRA.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	24885
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>The Government is in the process of recruiting a Chair to the Medicines and Healthcare products Regulatory Agency. The application and assessment process has concluded, and an announcement will be made when all required checks and approvals have been completed.</p><p>The process will run in accordance with the Civil Service Senior Appointments Protocol. A Civil Service Commissioner will chair this recruitment process in line with appointments of this level of seniority, and will consider the role of any incoming Chair in that process.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 24882 24883 24884 question first answered 13/05/2024 08:21:05 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1604 label Biography information for Mr Virendra Sharma